Phase 1/2 clinical study to assess the viability, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogenic adult stem mesenchymal cells of expanded adipose tissue pulsed with H2O2, in patients with acute traumatic spinal cord injury